UK stocks showed little movement today, with a slump in copper prices adversely affecting the metal sector.
The flagship FTSE 100 index barely moved, hovering around 7,699. This followed a minor gain of 0.3% on Friday. Mining companies such as Anglo American and Glencore saw their stocks reduce by 1-2%.
Pharmaceutical giant AstraZeneca, however, saw an increase of 1.3% in its share value after their blood-disorder drug, Voydeya, was approved by European regulators.
Similarly, GSK's stocks rose marginally by 0.6% upon announcing promising results from the EAGLE-1 Phase III trial for gepotidacin, a potentially groundbreaking oral antibiotic.
On the lower end, Bunzl's shares dipped by nearly 5%. The distribution and outsourcing company recently entered an agreement to acquire Nisbets in the UK and Pamark in Finland.
Homebuilders Persimmon and Barratt Developments also experienced a slight dip, falling by almost 2% and half a percent respectively. This follows the heels of an investigation into the sector by the antitrust watchdog.
